Imcd N.V.
Netherlands · NL0010801007 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Fair
- Revenue +6.4% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Fair
- It earned 13% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Fair
- Equity is 45% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
€4.7B
revenue
9.0%
operating margin
€278M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €3.4B | €4.6B | €4.4B | €4.7B |
| Operating profit | €305M | €462M | €429M | €425M |
| Net profit to shareholders | €207M | €313M | €292M | €278M |
| Earnings per share | €3.64 | €5.50 | €5.13 | €4.86 |
| Cash from operations | €196M | €299M | €420M | €279M |
| Capital spending | €6M | €11M | €21M | €14M |
| Cash | €178M | €222M | €394M | €525M |
| Total assets | €3.3B | €3.6B | €4.2B | €4.9B |
| Equity | €1.5B | €1.7B | €1.7B | €2.2B |
What they do
In the company's own words, from the annual report.
sales, marketing and distribution of speciality chemicals and pharmaceutical and food ingredients.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.